Last updated: 2026-09-05 22:08:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
PTC Therapeutics, Inc. (PTCT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $69.35, with a market capitalisation of $5.96B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $56.51 to $90.87. This page covers its latest market performance, valuation, price trends and company information.
$5.96B | |
$70.62 | |
$90.87 | |
$4.03 | |
$71.40 | |
453.92K | |
1.64M | |
-- | |
$90.87 | |
$56.51 | |
-- | |
-- |
PTC Therapeutics, Inc. (PTCT) last closed at $71.40 as of 2026-09-04 23:31:00, unchanged from the previous close of $71.40.
During the latest regular trading session, PTCT traded between $4.03 and $90.87, with a volume of 453.92K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, PTC Therapeutics, Inc. (PTCT) moved from $71.81 to $69.35, representing a decline of 3.43% ($2.46).
The stock traded between $68.76 and $72.68 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 743.11 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 37.4%
PTCT is currently trading at $69.35, placing it 37.4% of the way from its 52-week low of $56.51 to its 52-week high of $90.87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 991 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PTC Therapeutics, Inc. (PTCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.